Opinion
This case presents the following questions: whether a plaintiff, in a suit for personal injury caused by a defective drug, who is unaware of any specific facts establishing wrongful conduct on the part of any drug manufacturer, may delay bringing an action until she discovers such facts; whether a claim, otherwise barred by the statute of limitations, can be revived due to our decision in
Sindell
v.
Abbott Laboratories
(1980)
I. Facts
Plaintiff Jolly was bom in 1951. In 1972, she first learned that while she was in útero her mother had ingested the synthetic drag estrogen diethylstilbestrol (DES) for the prevention of miscarriage. Plaintiff was told in 1972 that DES daughters could suffer injuries. Therefore, she went to a DES clinic at the UCLA Medical Center for a checkup. She was diagnosed as having adenosis, a precancerous condition that required careful monitoring. In 1976, she had an abnormal pap smear and underwent a dilation and curettage, a surgical procedure to remove abnormal tissue. In 1978, plaintiff underwent a complete hysterectomy and a partial vaginectomy in order to remove malignancy. As of 1972, plaintiff was aware, or at least suspected, that her condition was a result of her mother’s ingestion of DES during pregnancy.
Starting in 1972, plaintiff attempted to discover the manufacturer of the DES ingested by her mother. Efforts were increased in 1976 and 1978 when plaintiff’s condition became acute. Unfortunately, the doctor who *1108 prescribed the drug had died, 1 and plaintiff was unable to locate his records. Although the dispensing pharmacist did remember filling the DES prescription, he did not recall or have records pertaining to the specific brand used. This was not unusual since DES was a fungible drug, that is, hundreds of pharmaceutical companies made DES from a single agreed formula. The hospital where plaintiff was born was of no assistance because plaintiff’s mother did not use DES while there.
At least as of 1978, plaintiff was aware of the pendency of one or more DES suits alleging that DES manufacturers were liable to those injured due to their failure to test or failure to warn. Although she believed that DES had caused her injuries and that those who marketed DES had wrongfully marketed a defective product, there is no conclusive evidence in the record to show that a reasonable investigation by plaintiff in 1978 would have disclosed specific proven facts that would establish any wrongful conduct on the part of a DES drug manufacturer. In fact, even today defendants allege that DES is not defective, but for purposes of summary judgment have admitted the allegation of some defectiveness.
Further, plaintiff believed that she had no cause of action if she could not identify the particular manufacturer of the drug her mother took during pregnancy. Because her efforts to identify that manufacturer were unsuccessful, plaintiff did not file suit.
In March 1980, we decided Sindell v. Abbott Laboratories, supra, 26 Cal.3d 588, and held that if a plaintiff could not identify the precise drug manufacturer of the ingested DES, she could state a cause of action against the DES manufacturers of a substantial percentage of the market share of the drug. Defendants would be liable, assuming the remaining material allegations in the complaint were proven, unless they could disprove their involvement. Almost one year after Sindell, plaintiff Jolly brought this action.
Defendants moved for summary judgment, asserting that the action was barred by Code of Civil Procedure section 340, subdivision (3), 2 setting forth a one-year statute of limitations period for an action “for injury . . . caused by the wrongful act or neglect of another.” Although conceding the applicability of the one-year statutory period, plaintiff denied that the suit was time-barred. She asserted that the statute did not commence until she *1109 learned of the Sindell decision, because only then did she realize that she would be able to successfully bring her claim.
Plaintiff maintained that Sindell created a new cause of action by redefining “causation.” Prior to Sindell, she claimed, only the specific manufacturer of the pills that were ingested was deemed to have “caused” the injury. After Sindell, according to plaintiff, it was the generic drug DES that “caused” the harm, and therefore all DES manufacturers were tortfeasors.
The trial court granted defendants’ motion and entered judgment in their favor. The Court of Appeal reversed, relying on its earlier decision in
Kensinger
v.
Abbott Laboratories
(1985)
II. The Kensinger Decision
As previously noted, both sides agree that the one-year limitations period of section 340, subdivision (3) applies to this case. Both sides also agree that the common law rule, that an action accrues on the date of injury
(Lambert
v.
McKenzie
(1901)
The Court of Appeal applied
Kensinger, supra,
However, the key point in Kensinger was its determination that one “critical fact” was knowledge of some wrongful conduct. Specifically, the court held that a plaintiff may have “no knowledge of facts indicating wrongdoing by a particular defendant. In such a situation, litigation might be premature for lack of knowledge of any factual basis for imputing fault to a manufacturer rather than ignorance of supportive legal theories. . . . [11] Knowledge of the occurrence and origin of harm cannot necessarily be equated with knowledge of the factual basis for a legal remedy. . . .” (171 Cal.App.3d at pp. 383-384; italics added.) Accordingly, the Kensinger court held that the statutory clock did not begin to tick until the plaintiff knew or reasonably should have known of the facts constituting wrongful conduct, as well as the fact of her injury and its relation to DES. 5 The Court of Appeal, applying Kensinger, held that it could not be said that “as a matter of law” Jolly was or should have been aware of facts establishing wrongdoing, e.g., “either failure to test or failure to warn,” until within one year of the date she filed suit.
The rule proposed in
Kensinger
goes too far.
6
Under the discovery rule, the statute of limitations begins to run when the plaintiff suspects or should suspect that her injury was caused by wrongdoing, that someone has done something wrong to her.
7
As we said in
Sanchez
and reiterated in
Gutierrez,
the limitations period begins once the plaintiff “ ‘ “has notice or
*1111
information of circumstances to put a reasonable person
on inquiry . .
. .”
(Gutierrez, supra,
39 Cal.3d at pp. 896-897, quoting
Sanchez, supra,
For example, in
Miller
v.
Bechtel Corp.
(1983)
Another case in point is
Gray
v.
Reeves
(1978)
The foregoing is fully consistent with the policy of deciding cases on the merits as well as the policies underlying the statute of limitations. In
Davies
v.
Krasna
(1975)
While resolution of the statute of limitations issue is normally a question of fact, where the uncontradicted facts established through discovery are susceptible of only one legitimate inference, summary judgment is proper.
(Christ
v.
Lipsitz
(1979)
Plaintiff’s contention that our decision in
Sindell
redefined “causation” and “wrongful,” providing the crucial “fact” necessary for her to suspect wrongdoing, is without merit.
Sindell, supra, 26
Cal.3d 588, is fully discussed below. At this point it is necessary only to point out the oft-stated rule that it is the discovery of facts, not their legal significance, that starts the statute. (See, e.g.,
Gutierrez, supra,
*1114 In sum, the limitations period begins when the plaintiff suspects, or should suspect, that she has been wronged. Here, plaintiff suspected as much no later than 1978. Because she did not file suit until 1981, her suit, unless otherwise saved, is time-barred. 13
III. The Effect of Sindell
Plaintiff’s major argument, which was summarily rejected by the trial court and the Court of Appeal, is that our landmark decision in
Sindell
v.
Abbott Laboratories, supra,
Plaintiff contends that prior to
Sindell, supra,
Defendants reply that this was not the intended effect of Sindell. They argue that Sindell merely shifted from plaintiff to defendants the burden of proving which manufacturer’s drug caused plaintiff’s injury.
There is merit in both contentions.
Sindell
is more than a mere “burden shifting” case. Although based in part on
Summers
v.
Tice
(1943)
At the same time, we did not create an entirely new tort, nor identify a new “product.” Sindell merely bridged the causal gap between DES manufacturers as a group and plaintiff’s injury. Where the actual manufacturer of the ingested DES is unknown, causation by joined manufacturers of a substantial share of the DES that a plaintiff’s mother might have taken would be presumed, subject, of course, to each drug manufacturer’s ability to rebut the presumption by proving that the actual pills in question were not its product.
We noted in Sindell that the trial court properly dismissed a drug company that did not manufacture any DES during the relevant time. (Id. at p. 612.) Plaintiff interprets this as merely establishing that the dismissed defendant engaged in no wrongful conduct during the relevant period and, hence, shares no liability. This interpretation is incorrect. A defendant who manufactured only capsules in a case where tablets were ingested would be similarly dismissed. Such a result would make no sense if Sindell were based on a new theory of wrongful conduct—a capsule manufacturer’s conduct would be equally culpable. In addition, under plaintiff’s theory carried to its logical extreme all drug companies would be liable even if plaintiff knew the actual manufacturer of the drug. Yet that clearly is not the law. 15
From the foregoing, it is clear that Sindell did not provide plaintiff with the critical “fact” that started the limitations period. Nor did it create a new tort with an independent starting date for purposes of the statute of limitations. Rather, Sindell demonstrated the legal significance of facts already known to plaintiff. The statute had started to run for plaintiff well before Sindell was decided.
At a less legalistic but more fundamental level, plaintiff argues, with some persuasive force, that prior to
Sindell
she could not have prevailed on her
*1116
suit. She notes that during the time that defendants argue her action would have been timely,
McCreery
v.
Eli Lilly & Co., supra,
The seminal case on point is
Monroe
v.
Trustees of the California State Colleges
(1971)
Shortly thereafter, Professor Monroe brought suit in part for back wages. We held that this portion of Professor Monroe’s suit was untimely because a change in the law applied only to timely filed claims; the change could not revive claims already barred by the statute of limitations.
(Monroe, supra, 6
Cal.3d at pp. 406-407.) Although prior to
Vogel
Professor Monroe was effectively precluded from bringing his claim, it was not “impossible” for him to do so. We held that “no legal obstacle barred a judicial challenge to [his] initial discharge” and that the “mere existence of a contrary precedent has never been considered sufficient to toll the statute of limitations.”
(Id.
at p. 408, fn. 5.) (Accord,
Estate of Horman
(1971)
In all of the above-cited cases, the court recognized that the rule may work a harsh result. Nonetheless, it is justified in three ways. First, the
*1117
rule encourages people to bring suit to change a rule of law with which they disagree, fostering growth and preventing legal stagnation. Second, the statute of limitations is not solely a punishment for slow plaintiffs. It serves the important function of repose by allowing defendants to be free from stale litigation, especially in cases where evidence might be hard to gather due to the passage of time. Third, to hold otherwise would allow virtually unlimited litigation every time precedent changed. For example, in
Li
v.
Yellow Cab Co.
(1975)
Plaintiff seeks to avoid application of the rule that contrary precedent does not toll the statute of limitations by noting that prior to each of the aforementioned cases there had been a decided policy that barred plaintiffs from the courts. Here, in contrast, no legislative or judicial policy was expressed to preclude DES victims who could not identify the manufacturer of the ingested drug from bringing suit. Plaintiff’s distinction is accurate, but irrelevant. Such a policy has never been articulated as a reason to enforce statutes of limitation following changes in the law, nor does this difference justify creating retroactivity reaching back to claims barred by res judicata or the statute of limitations.
Moreover, in early 1978, plaintiff’s legal situation was not as dismal as it initially appears. First, she was in no worse a position than Judith Sindell, who ultimately prevailed in changing the law. Second, there were other, more traditional theories available on which plaintiff could base her lawsuit, such as civil conspiracy or joint liability under
Summers
v.
Tice, supra,
Finally, even without using any of the above theories, plaintiff could have filed a timely complaint under section 474, which allows suit to be filed against a Doe party. From the time such a complaint is filed, the plaintiff has three years to identify and serve the defendant. (See
Altman
v.
Morris Plan Co.
(1976)
In sum, plaintiff’s argument that Sindell created or revived her cause of action must fail.
IV. Application of American Pipe
Relying on
American Pipe & Construction Co.
v.
Utah
(1974)
We have repeatedly directed that in the absence of controlling state authority, California courts should utilize the procedures of rule 23 of the Federal Rules of Civil Procedure (28 U.S.C.) to ensure fairness in the resolution of class action suits.
(Richmond
v.
Dart Industries, Inc.
(1981)
In American Pipe the State of Utah commenced a civil action, claiming that defendants conspired to rig steel and concrete pipe prices in violation of the Sherman Act. The suit purported to be a class action, brought on behalf of Utah’s public agencies and others who were end users of the pipe. On defendant’s motion, the district court denied class action status for failure to satisfy the numerosity requirement of rule 23(a)(1) of the Federal Rules of Civil Procedure. The public agencies who were alleged as class members then filed motions to intervene. The court denied the motions on statute of limitations grounds. The Ninth Circuit reversed.
The United States Supreme Court in a unanimous decision affirmed the circuit court: “We hold that in this posture, at least where class action status has been denied solely because of failure to demonstrate that ‘the class is so numerous that joinder of all members is impracticable,’ the commencement of the original class suit tolls the running of the statute for all purported members of the class who make timely motions to intervene after the court has found the suit inappropriate for class action status.”
(American Pipe, supra,
In
Bangert
v.
Narmco Materials, Inc., supra,
The Court of Appeal reversed. Citing
American Pipe,
the court held that the filing of the complaint tolled the running of the statute of limitations for all members of the purported class until class action certification was denied, even though, unlike
American Pipe,
denial was not for lack of numerosity, but for insufficient community of interest.
(Bangert
v.
Narmco Materials, Inc., supra,
Plaintiff urges us to follow the Bangert court’s extension of American Pipe so as to find that the filing of the Sindell class action tolled the statute of limitations applicable to her individual suit. To resolve this issue, we need to consider both the nature of the Sindell action and the rationale underlying American Pipe.
Judith Sindell filed suit in 1976. She purported to be suing on her own behalf and, “with respect to certain relief,” on behalf of a class of women allegedly similarly situated. For herself, individually, Sindell claimed damages for specific personal injury suffered as a result of her mother’s ingestion of DES during pregnancy. In her cause of action relating to the class claims, Sindell described the class as female residents of California “who have been exposed to DES before birth and who may or may not know that fact or danger, and as a result of which, have or may have contracted or in the future may contract adenocarcinoma or vaginal or cervical adenosis or precancerous tumors of the breast or cancer of the bladder.” For the class, Sindell sought only declaratory relief and an order directing defendants to publicize the dangers of DES and the necessity of medical evaluations and to fund the establishment and maintenance of clinics to provide free examinations to the DES daughters.
Six years later, in 1982, the trial court denied certification. As reason, the court cited, in relevant part, the lack of commonality among class members on issues of proximate cause, extent of injury, and appropriate medical examination or treatment. 17 “As a general rule,” the court observed, “so- *1121 called ‘mass accidents’ or ‘common disasters’ are considered not appropriate for class litigation. This inappropriateness is based upon the overwhelming uniqueness of the issues stemming from the necessity for the trier to hear and determine individually each victim’s injuries, his suffering, financial loss, etc. Thus even though a common question may be involved (e.g., the defendant’s tort) the matter is not suitable for a class action.”
The question to be asked, then, is whether the
Sindell, supra,
Underlying the tolling rule of
American Pipe
were two major policy considerations. The first was the protection of the class action device. In cases where class certification is denied for what the high court characterized as “subtle factors,” unforeseeable by class members, a rule that failed to protect putative class members from the statute of limitations after denial of certification would induce potential class members to “file protective motions to intervene or to join in the event that a class was later found unsuitable,” depriving class actions “of the efficiency and economy of litigation which is a principal purpose of the procedure.”
(American Pipe, supra,
The second consideration involved the effectuation of the purposes of the statute of limitations. “The policies of ensuring essential fairness to defendants and of barring a plaintiff who has ‘slept on his rights,’ ” the high court stated, “are satisfied when, as here, a named plaintiff who is found to be representative of a class commences a suit and thereby notifies the defendants not only of the substantive claims being brought against them, but also of the number and generic identities of the potential plaintiffs who may participate in the judgment.” (414 U.S. at pp. 554-555 [
The tension between these two considerations, as at least one commentator has observed (Comment,
supra,
48 U. Chi. L.Rev. 106, 110-111), has led
*1122
lower courts in applying
American Pipe
to use different approaches. Some courts concentrate on the protection of the class action device: “We are persuaded that implicit in the Supreme Court’s
American Pipe
decision was the Court’s determination that ‘effectuation of the purpose of litigative efficiency and economy,’ (which Rule 23 was designed to perform) transcends the policies of repose and certainty behind statutes of limitations. [Citation.]”
(Appleton Elec. Co.
v.
Graves Truck Line, Inc.
(7th Cir. 1980)
Considering both policy considerations—protecting the efficiency and economy of litigation and protecting the defendant from unfair claims—we decline to extend the tolling doctrine of
American Pipe, supra,
*1123
This court has held that the ultimate determination of whether a class action is appropriate turns on the existence and extent of common questions of law and fact.
(City of San Jose
v.
Superior Court
(1974)
The same reasons that render certification of mass-tort claims generally inappropriate render inappropriate the application and extension of
American Pipe, supra,
This deficiency in Sindell’s class action suit is alone sufficient to deny plaintiff relief under
American Pipe.
As Justice Blackmun, in his concurrence in
American Pipe,
cautioned: “Our decision . . . must not be regarded as encouragement to lawyers in a case of this kind to frame their pleadings as a class action, intentionally, to attract and save members of the purported class who have slept on their rights. Nor does it necessarily guarantee intervention for all members of the purported class, [fl] As the Court has indicated, the purpose of statutes of limitations is to prevent surprises ‘through the revival of claims that have been allowed to slumber until evidence has been lost, memories have faded, and witnesses have disappeared.’ [Citations.]”
(American Pipe, supra,
Justice Blackmun’s admonition was echoed by three of his colleagues in the principal United States Supreme Court decision interpreting
American Pipe—Crown, Cork & Seal Co.
v.
Parker, supra,
Our position in the present case ensures that the abuse warned of by Justice Blackmun will not occur. By refusing to extend
American Pipe’s
*1125
tolling doctrine to allow the instant suit, we heed Justice Blackmun’s admonishment to district judges to exercise discretion in applying the
American Pipe
rule in order to “prevent the type of abuse mentioned above and [to] preserve a defendant whole against prejudice arising from claims for which he has received no prior notice.” (
In light of our disposition, we need not address the broader question whether in any personal injury mass-tort case the filing of a class action complaint can serve to toll the statute of limitations for putative class members when the class ultimately is denied certification for lack of commonality. We observe, however, that because personal-injury mass-tort class-action claims can rarely meet the community of interest requirement in that each member’s right to recover depends on facts peculiar to each particular case, such claims may be presumptively incapable of apprising defendants of “the substantive claims being brought against them”
(American Pipe, supra,
*1126
For the reasons previously stated, we hold that the
American Pipe
tolling rule
(supra,
V. Conclusion
The judgment of the Court of Appeal is reversed. The cause is remanded with instructions to affirm the judgment of the trial court in favor of defendants.
Lucas, C. J., Mosk, J., Broussard, J., Arguelles, J., Eagleson, J., and Kaufman, J., concurred.
Notes
The doctor died prior to 1978. The record does not set forth the exact date or year of his death.
All further statutory references are to the Code of Civil Procedure unless otherwise indicated.
The court stated: “We decline to interpret Sindell, as plaintiff proposes, as creating a new cause of action by defining generic DES as the causation element.”
Defendants argue that the statute should commence when the plaintiff knows of her injury and its
factual
cause. Although that position has been adopted in some jurisdictions (see e.g.,
United States
v.
Kubrick
(1979)
Plaintiff maintains that the
Kensinger
rule was foreshadowed by prior California authority. However, the cases that she cites do no more than set out the discovery rule as previously described. They do not directly address the question of whether a suspicion of wrongdoing without knowledge of particular facts establishing misconduct will begin the statutory period. (See
Young
v.
Haines
(1986)
We recognize that some jurisdictions have adopted rules similar to that set out in
Kensinger.
(See, e.g.,
Anthony
v.
Abbott Laboratories
(R.I. 1985)
In this context, “wrong,” “wrongdoing,” and “wrongful” are used in their lay understanding.
To the extent that
Kensinger, supra,
Specifically, the following dialogue was contained in plaintiff’s deposition and was part of the motion for summary judgment:
“Q: Why at that time were you interested in obtaining more information [about the DES ingested by plaintiff’s mother]?
“A: To see if I had any type of recourse.
“Q: You mean in terms of making a claim or recovering from someone for your injury?
“A: Sure, yes.
“Q: In 1978 did you feel that you should have some kind of recourse?
“A: Yes.
“Q: You felt that someone had done something wrong to you?
“A: Yes.
“Q: And that you should be compensated for it?
“A: Yes.
it
“Q: You believed at that time, in 1978, that DES was a defective drug, is that right?
“A: Yes.”
See, e.g.,
The Cancer That Doctors Caused,
San Francisco Examiner (Sept. 12, 1979);
DES—A Chemical Menace to the Unborn,
San Francisco Chronicle (Dec. 18, 1978);
Millions of Women to Be Notified of DES Cancer Risk,
Los Angeles Times (Oct. 5, 1978);
Effects of DES; Legal Battles and Human Suffering,
Oakland Tribune (April 28, 1977);
Major U.S. Companies Sued for Damage in Class Action,
Wall Street Journal (Sept. 18, 1974); Questions and Answers about DES Exposure Before Birth (DESAD Project), Department of Health, Education, and Welfare Publication No. 76-1118 (1976); Information for Physicians, DES Exposure In Utero, Department of Health, Education, and Welfare Publication No. 76-1119 (1976);
Gray
v.
United States
(S.D. Tex. 1978)
This case does not present us with a situation where the plaintiff conducted a prompt investigation and brought suit as soon as the results of the investigation were known, but even so filed her claim after the limitations period had expired. In such a situation, the cause of action might still be timely. (See
Whitfield
v.
Roth
(1974)
The following colloquy took place at plaintiff’s deposition:
“Q: As of the time you first called Mr. Schulz’s firm in 1980, had you learned anything new about your mother’s use of DES of which you were not aware in 1978?
“A: Not that I remember.
“Q: Had you learned anything about the drug DES, that is its use or the manufacture, testing of the drug, the effect of the drug, during that period of time between March ’78 and the time you contacted the attorney in 1980?
“A: Not that I remember.
“Q: During that same period of time had you learned any information as to what company made the drug?
“A: Not that I remember.
“Q: Is it correct then that the only thing that you learned new or differently pertaining to DES or your injury between March of 1978 and the time you called the attorneys in 1980 was that the Court ruled you could file a lawsuit even if you couldn’t identify the manufacturer?
“A: Correct.”
Plaintiff’s failure to file suit despite her suspicion of wrongdoing is not surprising in the context of this case. By her own admission, her real reason for delaying action was that she did not know whom to sue, not that she did not know whether to sue. See discussion, post, this page.
In Summers, we held that an innocent plaintiff who could not identify which of two negligent hunters shot him, but was sure that one of them was the culprit, could bring suit by joining both. The burden then shifted to each defendant to show that he did not cause the injury.
Such a result surely would be beneficial to plaintiffs. For example, some drug companies are judgment proof or beyond the court’s jurisdiction. Under plaintiff’s interpretation of Sin-dell carried to its logical extreme, that would not prevent a plaintiff from recovering from other DBS manufacturers even if she knew that they did not produce the ingested DBS. However, such a result is foreclosed.
We take judicial notice (Evid. Code, § 452, subd. (d)) of the pleadings, files, and orders filed in Sindell (L.A. County Super. Ct., No. C169127) and in Rogers v. Rexall Drug Co., et al. (Ventura County Super. Ct., No. 61220), consolidated with Sindell on appeal (see Sindell, supra, 26 Cal.3d at p. 597).
Other reasons cited by the court were the amorphous nature of the alleged class, which would necessitate substantial postjudgment litigation in order to identify class members; the inequity of a class action, in that unsuspecting class members unaware of the pendency of the lawsuit and their right to opt out would forfeit their right to claim very substantial damages; and plaintiff’s nonmembership in the class, having “carefully excluded herself,” in that the *1121 damages remedy she sought was mutually exclusive from the medical evaluation she sought for the class. (Sindell, supra, ruling upon motion for certification.)
Although in
Rogers
v.
Abbott Laboratories,
consolidated with
Sindell, supra,
Although we believe class actions can rarely be appropriate for resolution of mass tort claims, that is not to say some of the benefits of the class action device cannot be implemented by other means, such as coordination proceedings (§ 404 et seq.; Cal. Rules of Court, rule 1501 et seq.). In such type of proceedings common issues can be determined, yet each individual plaintiff is responsible for the proof of particular facts applicable to that particular plaintiff. (See generally, 4 Witkin, Cal. Procedure (3d ed. 1985) Pleading, §§ 309-329, pp. 361-380.)
Insofar as
Bangert
v.
Narmco Materials, Inc., supra,
